{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:27:47Z","timestamp":1787110067703,"version":"build-2736575974"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802874"],"award-info":[{"award-number":["81802874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260548"],"award-info":[{"award-number":["82260548"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011827","name":"Guangxi Medical University","doi-asserted-by":"publisher","award":["2021006"],"award-info":[{"award-number":["2021006"]}],"id":[{"id":"10.13039\/501100011827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["GKEAB18221019"],"award-info":[{"award-number":["GKEAB18221019"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2024GXNSFAA010347"],"award-info":[{"award-number":["2024GXNSFAA010347"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105404","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:31:17Z","timestamp":1780417877000},"page":"105404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Research advances in dual-conversion therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"225","author":[{"given":"Jingren","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangye","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030733","article-title":"Liver resection and transplantation following yttrium-90 radioembolization for primary malignant liver tumors: a 15-year single-center experience","volume":"15","author":"Aliseda","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105404_bib2","article-title":"Hepatocellular carcinoma: molecular mechanisms and targeted therapies","volume":"55","author":"Alqahtani","year":"2019","journal-title":"Med. (Kaunas. )"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib3","article-title":"90)Y-\/(166)Ho- 'radiation lobectomy' for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics","volume":"6","author":"Andel","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.critrevonc.2026.105404_bib4","first-page":"824","article-title":"Chinese expert consensus on the whole-course management of hepatocellular carcinoma(2023 edition)","volume":"07","author":"Association","year":"2023","journal-title":"Chin. J. Dig. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ags3.12414","article-title":"Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma","volume":"5","author":"Beppu","year":"2021","journal-title":"Ann. Gastroenterol. Surg."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105404_bib6","article-title":"Predictive and prognostic factors in HCC patients treated with sorafenib","volume":"55","author":"Brunetti","year":"2019","journal-title":"Med. (Kaunas. )"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105404_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11605-022-05551-2","article-title":"Liver venous deprivation versus portal vein embolization before major hepatectomy for colorectal liver metastases: a retrospective comparison of short- and medium-term outcomes","volume":"27","author":"Cassese","year":"2023","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.critrevonc.2026.105404_bib9","article-title":"Associated liver partition and portal vein ligation for staged hepatectomy: a review","volume":"5","author":"Chan","year":"2019","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib10","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib11","first-page":"2021","article-title":"Downstaging therapies for unresectable hepatocellular carcinoma prior to hepatic resection: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105404_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004389","article-title":"Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models","volume":"10","author":"Chen","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1478-3231.2010.02436.x","article-title":"Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma","volume":"31","author":"Choi","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.critrevonc.2026.105404_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2458679","article-title":"The rising era of immune checkpoint inhibitors in myelodysplastic syndromes","volume":"2018","author":"Chokr","year":"2018","journal-title":"Adv. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5114\/ceh.2021.106521","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in colorectal liver metastases: review of the literature","volume":"7","author":"Coco","year":"2021","journal-title":"Clin. Exp. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib19","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fradi.2021.736056","article-title":"Induction of robust future liver remnant hypertrophy before hepatectomy with a modified liver venous deprivation technique using a trans-venous access for hepatic vein embolization","volume":"1","author":"Degrauwe","year":"2021","journal-title":"Front. Radiol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105404_bib20","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1097\/JS9.0000000000000654","article-title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study","volume":"109","author":"Deng","year":"2023","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s12885-020-07065-z","volume":"20","author":"Deshayes","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105404_bib23","article-title":"Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"102","author":"Du","year":"2023","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2026.105404_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1431211","article-title":"Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy","volume":"15","author":"Du","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/JHC.S358082","article-title":"Systemic therapy for hepatocellular carcinoma: current updates and outlook","volume":"9","author":"Fan","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105404_bib26","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105404_bib27","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4240\/wjgs.v15.i9.2089","article-title":"Dual transformation therapy for giant hepatocellular carcinoma: two case reports and review of literature","volume":"15","author":"Gao","year":"2023","journal-title":"World J. Gastrointest. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105404_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.21037\/hbsn-21-381","article-title":"Comment on: liver venous deprivation (LVD) or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)? A retrospective multicentric study","volume":"10","author":"Girard","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/cco-23-140","article-title":"Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review","volume":"13","author":"Hall","year":"2024","journal-title":"Chin. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib30","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1038\/s41598-022-12076-w","article-title":"EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells","volume":"12","author":"He","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105404_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijsu.2020.04.009","article-title":"Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure for colorectal liver metastasis","volume":"82s","author":"Hernandez-Alejandro","year":"2020","journal-title":"Int. J. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105404_bib32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7150\/ijbs.39725","article-title":"Mesenchymal stromal cells promote liver regeneration through regulation of immune cells","volume":"16","author":"Hu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105404_bib33","article-title":"Lenvatinib versus bevacizumab when combined with PD-1\/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib34","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000531820","article-title":"Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD","volume":"13","author":"Ikeda","year":"2024","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13014-023-02270-z","article-title":"Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study","volume":"18","author":"Ji","year":"2023","journal-title":"Radiat. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105404_bib37","first-page":"2306","article-title":"Systemic therapy for advanced hepatocellular carcinoma","volume":"40","author":"Jiahao","year":"2024","journal-title":"J. Clin. Hepatol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105404_bib38","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105404_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007106","article-title":"Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma","volume":"11","author":"Kaya","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105404_bib41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijsu.2018.01.042","article-title":"Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review","volume":"52","author":"Khan","year":"2018","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.hpb.2021.08.948","article-title":"Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality","volume":"24","author":"Khan","year":"2022","journal-title":"HPB (Oxf. )"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000529574","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000535154","article-title":"A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: extended analysis of study 116","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"issue":"10126","key":"10.1016\/j.critrevonc.2026.105404_bib45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.critrevonc.2026.105404_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib47","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jss.2016.03.032","article-title":"Liver regeneration after different degrees of portal vein ligation","volume":"203","author":"Lauber","year":"2016","journal-title":"J. Surg. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib49","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.21037\/jgo-22-882","article-title":"Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma","volume":"14","author":"Lee","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105404_bib50","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jamcollsurg.2014.04.022","article-title":"Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure","volume":"219","author":"Leung","year":"2014","journal-title":"J. Am. Coll. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13014-022-02075-6","article-title":"Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study","volume":"17","author":"Li","year":"2022","journal-title":"Radiat. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105404_bib53","first-page":"2943","article-title":"Research advances in systemic therapy for advanced hepatocellular carcinoma","volume":"37","author":"Li","year":"2021","journal-title":"J. Clin. HEPATOLOGY"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036865","article-title":"The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis","volume":"103","author":"Li","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2026.105404_bib55","unstructured":"Liang, X., (n.d.) Concept innovations and challenges in surgical treatment of hepatocellular carcinoma. Chinese Journal of General Surgery 30((7) 753-760."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105404_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12247665","article-title":"From conversion to resection for unresectable hepatocellular carcinoma: a review of the latest strategies","volume":"12","author":"Liang","year":"2023","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jnci\/djaa119","article-title":"Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review","volume":"113","author":"Lim","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib58","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jleuko\/qiae092","article-title":"BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer","volume":"116","author":"Lin","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.106094","article-title":"Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia","volume":"102","author":"Liu","year":"2022","journal-title":"Int. J. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105404_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3892\/ol.2023.14094","article-title":"A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105404_bib61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105404_bib62","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"issue":"09","key":"10.1016\/j.critrevonc.2026.105404_bib63","first-page":"1725","article-title":"Strategies and practice of conversion therapy for hepatocellular carcinoma","volume":"40","author":"Ma","year":"2024","journal-title":"J. Clin. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3892\/ol.2025.15088","article-title":"Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: a systematic review of current evidence and future prospects (Review)","volume":"30","author":"Ma","year":"2025","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae209","article-title":"Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"30","author":"Ma","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105404_bib66","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3389\/fimmu.2020.01689","article-title":"TCR redirected T cells for cancer treatment: achievements, hurdles, and goals","volume":"11","author":"Manfredi","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105404_bib67","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jvir.2018.01.780","article-title":"Analysis of preoperative portal vein embolization outcomes in patients with hepatocellular carcinoma: a single-center experience","volume":"29","author":"Marti","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/JHC.S298538","article-title":"Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma","volume":"8","author":"Mei","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105404_bib69","doi-asserted-by":"crossref","first-page":"350","DOI":"10.21037\/hbsn-20-394","article-title":"Optimization of the future remnant liver: review of the current strategies in Europe","volume":"10","author":"Memeo","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib70","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.28988","article-title":"Hepatostat: liver regeneration and normal liver tissue maintenance","volume":"65","author":"Michalopoulos","year":"2017","journal-title":"Hepatology"},{"issue":"02","key":"10.1016\/j.critrevonc.2026.105404_bib71","first-page":"281","article-title":"Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy","volume":"22","author":"Minjie","year":"2023","journal-title":"Chin. J. Dig. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.70513","article-title":"The adverse impact of tyrosine kinase inhibitors on wound healing and repair","volume":"22","author":"Nahm","year":"2025","journal-title":"Int. Wound J."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105404_bib73","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2014.03.038","article-title":"Building the multidisciplinary team for management of patients with hepatocellular carcinoma","volume":"13","author":"Naugler","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105404_bib74","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1007\/s00259-022-05920-8","article-title":"Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib","volume":"49","author":"\u00d6cal","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105404_bib76","first-page":"829","article-title":"The clinical value of terminal branches portal vein embolization for hepatocellular carcinoma with insufficient future liver remnant","volume":"59","author":"Peng","year":"2021","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib77","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12885-021-08033-x","article-title":"PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma","volume":"21","author":"Pinato","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib78","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1138570","article-title":"TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial","volume":"13","author":"Qi","year":"2023","journal-title":"Front. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105404_bib80","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105404_bib81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib82","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41467-024-46835-2","article-title":"Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma","volume":"15","author":"Ramirez","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105404_bib83","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/era.09.41","article-title":"Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial","volume":"9","author":"Rimassa","year":"2009","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010055","article-title":"History and evolution of Yttrium-90 radioembolization for hepatocellular carcinoma","volume":"8","author":"Saini","year":"2019","journal-title":"J. Clin. Med."},{"issue":"10474","key":"10.1016\/j.critrevonc.2026.105404_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10471","key":"10.1016\/j.critrevonc.2026.105404_bib86","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/S0140-6736(24)02600-X","article-title":"Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy","volume":"404","author":"Schoenfeld","year":"2025","journal-title":"Lancet"},{"issue":"02","key":"10.1016\/j.critrevonc.2026.105404_bib87","first-page":"184","article-title":"Conversion therapy strategies for hepatocellular carcinoma with insufficient future liver remnant","volume":"24","author":"Shang Changzhen","year":"2025","journal-title":"Chin. J. Dig. Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105404_bib88","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41419-021-04263-w","article-title":"Loss of numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling","volume":"12","author":"Shu","year":"2021","journal-title":"Cell. Death Dis."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105404_bib89","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1007\/s00268-012-1522-3","article-title":"Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study","volume":"36","author":"Siriwardana","year":"2012","journal-title":"World J. Surg."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105404_bib90","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.3390\/cancers16173024","article-title":"Conversion therapy to transplant or surgical resection in patients with unresectable hepatocellular carcinoma treated with boosted dose of Yttrium-90 radiation segmentectomy","volume":"16","author":"Son","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105404_bib91","doi-asserted-by":"crossref","first-page":"90","DOI":"10.37349\/etat.2022.00073","article-title":"Liver venous deprivation for resection of advanced hilar cholangiocarcinoma-a case report and review of the literature","author":"Stoyanova","year":"2022","journal-title":"Explor. Target. Antitumor Ther. 3(1"},{"key":"10.1016\/j.critrevonc.2026.105404_bib92","article-title":"Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib94","article-title":"Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade","volume":"32","author":"Tesfay","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib95","first-page":"190","article-title":"Liver cancer: lenvatinib non-inferior to sorafenib for hepatocellular carcinoma","volume":"15","author":"Thomas","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3_","key":"10.1016\/j.critrevonc.2026.105404_bib96","article-title":"Safety and efficacy of external beam radiotherapy in hepatocellular carcinoma patients previously treated with yttrium-90 radioembolization","volume":"42","author":"Thonglert","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"ementum 3","key":"10.1016\/j.critrevonc.2026.105404_bib98","first-page":"30","article-title":"Surgical treatment of hepatocellular carcinoma","volume":"33","author":"V\u00e1clav","year":"2020","journal-title":"Klin. Onkol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105404_bib99","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105404_bib100","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.3390\/curroncol30120734","article-title":"Safety and efficacy of concurrent atezolizumab\/bevacizumab or nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma","volume":"30","author":"Villalobos","year":"2023","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib101","article-title":"Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: from clinical aspects to dosimetry","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105404_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.741352","article-title":"Sequential portal vein embolization and percutaneous radiofrequency ablation for future liver remnant growth: a minimally invasive alternative to ALPPS Stage-1 in treatment of hepatocellular carcinoma","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Surg."},{"key":"10.1016\/j.critrevonc.2026.105404_bib103","article-title":"An in-depth analysis of research on posthepatectomy liver failure (2006-2024): exploring trends and future directions through a bibliometric approach","volume":"12","author":"Wu","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105404_bib104","unstructured":"Xingsheng, C.Y.H.B.L., (n.d.) Progress in the application of associating liver partition and portal vein ligation for staged hepatectomy. JOURNAL OF NANJING MEDICAL UNIVERSITY(Natural Sciences) 42((6) 881-896."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105404_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004790","article-title":"Identification of novel HLA-A*11:01-restricted HPV16 E6\/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy","volume":"10","author":"Xiong","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib106","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1038\/s41598-025-88813-8","article-title":"Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma","volume":"15","author":"Xue","year":"2025","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105404_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250054","article-title":"Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma","volume":"53","author":"Ye","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105404_bib108","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/cancers16132401","article-title":"The impact of local control on overall survival after Y-90 selective internal radiotherapy of liver metastases in oligometastatic cancer: a retrospective analysis","volume":"16","author":"Yeakel","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib109","first-page":"168","article-title":"Conversion therapy for hepatocellular carcinoma: from unresectable to resectable","volume":"46","author":"Yongyi","year":"2025","journal-title":"ACADEMIC J. Nav. Med. Univ."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib110","first-page":"1053","article-title":"Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers","volume":"18","author":"Yu","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib111","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105404_bib112","article-title":"Sequential hepatectomy for hepatocellular carcinoma with inadequate future-liver-remnant after portal vein ligation in combination with apatinib plus camrelizumab (PLACES): a single-arm prospective pilot study","author":"Zeng","year":"2025","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105404_bib113","doi-asserted-by":"crossref","first-page":"180","DOI":"10.21037\/hbsn-2021-7","article-title":"Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?","volume":"10","author":"Zhang","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.critrevonc.2026.105404_bib114","article-title":"Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105404_bib115","article-title":"HGF\/c-Met: a key promoter in liver regeneration","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib116","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-024-01500-2","article-title":"Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies","volume":"24","author":"Zheng","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105404_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1657371","article-title":"Preoperative TACE with PD-1 inhibitors and TKIs in beyond \"up-to-seven\" hepatocellular carcinoma: a propensity score matched analysis","volume":"16","author":"Zhong","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105404_bib118","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1038\/s41598-023-27824-9","article-title":"The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105404_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.7533","article-title":"Conversion therapy for massive hepatocellular carcinoma: a case report and literature review","volume":"11","author":"Zhou","year":"2023","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105404_bib120","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.53730\/ijhs.v7nS1.14563","article-title":"Clinical application of transarterial chemoembolization combined with terminal branches portal vein embolization in planned hepatectomy","volume":"7","author":"Zhu","year":"2023","journal-title":"Int. J. Health Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105404_bib121","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105404_bib122","first-page":"2173","article-title":"Research advances in systemic therapy for hepatocellular carcinoma in the era of precision medicine","volume":"36","author":"Zhu","year":"2020","journal-title":"OURNAL Clin. HEPATOLOGY"},{"issue":"4_","key":"10.1016\/j.critrevonc.2026.105404_bib123","article-title":"Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: a multicenter, open-label, randomized, phase 2 study (CAP-ACE)","volume":"43","author":"Zhu","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105404_bib124","article-title":"Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients","volume":"10","author":"Zou","year":"2023","journal-title":"Adv. Sci. (Weinh. )"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:49:49Z","timestamp":1787107789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":124,"alternative-id":["S104084282600291X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105404","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research advances in dual-conversion therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105404"}}